EcoDrugPlus

Integrin Subunit Alpha 4

Ensembl ID : ENSTNIG00000003535
Gene Symbol: ITGA4
2 Cross references
225 Possible Orthologues:

Integrin Subunit Alpha 5

Ensembl ID : ENSTNIG00000004387
Gene Symbol: ITGA5
2 Cross references
197 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSTNIG00000009476
Gene Symbol: ITGB6
2 Cross references
206 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSTNIG00000012530
Gene Symbol: ITGA5
2 Cross references
206 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSTNIG00000019388
Gene Symbol: ITGAV
2 Cross references
237 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSTNIG00000008718
Gene Symbol: ITGB1A
2 Cross references
213 Possible Orthologues:

Integrin, Beta 1b.1

Ensembl ID : ENSTNIG00000007973
Gene Symbol: ITGB1B.1
2 Cross references
228 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSTNIG00000011540
Gene Symbol: ITGB5
2 Cross references
205 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSTNIG00000015983
Gene Symbol: IRAK4
2 Cross references
202 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSTNIG00000011558
Gene Symbol: IDH1
2 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSTNIG00000019241
Gene Symbol: IDH2
2 Cross references
207 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSTNIG00000011366
Gene Symbol: IDH2
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).